Skip to Content

Nivolumab BMS

Active Substance: nivolumab
Common Name: nivolumab
ATC Code: L01XC17
Marketing Authorisation Holder: Bristol-Myers Squibb Pharma EEIG
Active Substance: nivolumab
Status: Withdrawn
Authorisation Date: 2015-07-20
Therapeutic Area: Carcinoma, Non-Small-Cell Lung
Pharmacotherapeutic Group: Antineoplastic and immunomodulating agents, monoclonal antibodies

Therapeutic Indication

Nivolumab BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.

The marketing authorisation for Nivolumab BMS has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.